A Trial of SHR3162 Combined With Apatinib Mesylate Tablets or SHR3162 Monotherapy in Patients With Metastatic Castration Resistant Prostate Cancer

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
Main research purpose: To evaluate the effectiveness of Fluzoparib combined with apatinib mesylate in the treatment of patients with metastatic castration-resistant prostate cancer.
Epistemonikos ID: 94a002fa39f4b997c6d44c181815bd35c7217550
First added on: May 08, 2024